scioPhospho: protein + phosphorylation profiling

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation.



  • 900 highly relevant proteins are profiled in a single assay
  • Phosphorylation status combined with protein expression levels
  • Tyrosine, serine and threonine phosphorylation
  • Analysis of individual phosphorylation types available
  • "Sample-to-result" service
  • Comprehenisive data analysis and presentation
  • Individualised study report
Protein abundance levels and phosphorylation status for one individual protein out of 900 proteins tested



  • High-content screening of proteins and phosphorylation is time and ressource efficient
  • Direct comparability through protein expression and phosphorylation level analysis in a single assay
  • Complete analysis from minimal sample volume
  • Coverage of important
    • Signalling pathways
    • Transcription factors
    • Receptor molecules
    • Kinases
  • Individual data analysis options available
    • Protein interaction network analysis
    • Biological and pathway classification 
    • Lists with differential proteins and phosphorylation levels
  • Variety of sample formats possible without the potential bias of a sample fractionation or a sample depletion
  • Results presented in a publication-ready format



  • T cell activation
  • Tissue treatment response
  • Cell cycle regulation
  • Oxidative stress response
  • Cell adhesion and motility
  • Phosphorylation profiling of various signalling pathways:
    • FAK phosphorylation
    • PI3K-AKT pathway
    • p53 pathway regulation
    • Alzheimer pathway regulation






Case study

Eight treated cell line samples were compared with 8 control samples. Several proteins were identified as differentially expressed (x-axis) and/or phosphorylated (y-axis). While the left plot provides an overview on expression / phosphorylation differences for all tested proteins in the two sample groups, individual levels are depicted in the plots on the right. The sample status is indicated as C = control or T = treated.



Reference customers

  Christopher Y. Park, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, USA

  Prof. Dr. Mathias Heikenwälder, German Cancer Research Center, Heidelberg, Germany

  Dr. Caroline Pabst. University Hospital Halle, Germany



More information

  Download our scioPhospho or scioDiscover service brochure.

  Information on protein and pathway content / coverage.

  Get in touch to answer any remaining questions.

  Ask for a quotation to get your study started.



Which sample types can be analysed ?

With the scioPhospho service a variety of samples can be analysed:Sample-to-result service

  • fresh frozen tissue samples
  • cellular content
  • cerebrospinal fluid
  • plasma / serum
  • additional sample types on request



Sample-to-result service

Within our analysis service, we will not only carry out the microarray experiments but also support you with a suggestion for an appropriate microarray study design as well as with the sample selection process in order to address your scientific question in the optimal way. Within 3-4 weeks after receipt of your samples you will receive a customised study report including a statistical analysis.

Our analysis service includes:

  • definition of an appropriate study design
  • sample preparation
  • protein extraction
  • protein concentration measurements
  • protein quality control
  • sample labelling
  • sample purification
  • incubation of the samples on antibody microarrays
  • microarray scanning
  • raw data acquisition
  • data normalisation
  • data analysis including cluster analysis
  • statistical testing for differentially abundant proteins
  • statistical testing for differentially phosphorylated proteins
  • comprehensive study report









New article | Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

| July 2016 | One of our customer projects was published in Cancer Research. In this study Bakdash et al. analysed the expansion of a BDCA1+CD14+ myeloid cell population in the context of immune therapy of melanoma. Within this study a protein profiling of cellular patient samples was performed with scioCD antibody arrays.

Interview | Advanced Biomarkers for Precision Medicine

New article | Analysis of the blood protein profile in B-cell lymphoma patients

| 12.12.2013 | There is a new article in the current issue of Proteomics Clinical Applications on an analysis of the blood protein profile of different B-cell lymphoma using complex antibody microarrays. 200 blood samples from patients with Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) as well as healthy controls were analysed and compared with each other. The study identified proteins with discriminating power among the different lymphoma types, as well as subgroups within each lymphoma entity.

New article | Prediction of recurrence in bladder cancer

| 08.05.2014 | In a study published in Proteomics we identified proteins with differential abundance in bladder tumours with and without a local recurrence using antibody array technology. Next to interesting differences of the two tumour subtypes from a scientific point of view, we found a protein biomarker signature with high potential for a prognosis. This could enabling urologists in future to adjust the therapy and surveillance scheme accordingly. Further validation studies are ongoing. →Case study report